Skip to main content
Menu
US

HTRF α-SMA Detection Kit, 500 Assay Points

The Alpha-SMA kit is designed for the accurate quantitative measurement of Alpha-Smooth Muscle Actin produced by cells.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Part number: 62ASMAPEG
Unit Size: 500 Assay Points
List price: USD 1,919.00
Your price:
USD 1,919.00
USD 1,919.00 /each
Part number: 62ASMAPEH
Unit Size: 10,000 Assay Points
List price: USD 18,260.00
Your price:
USD 0.00
USD 18,260.00 /each

Overview

After tissue injury, TGF-beta locally released by inflammatory cells activates resident fibroblasts or quiescent HSCs (hepatic stellate cells). This leads to their differentiation into myofibroblasts, whose role is to migrate into the damaged tissue and synthesize ECM (extracellular matrix) components to repair the wound. Myofibroblasts are characterized by de novo expression of alpha-SMA, which is incorporated into actin stress fibers and confers a high contractile activity to the cells. Chronic tissue injury leads to persistent de novo formation of myofibroblasts (alpha-SMA+), excessive contraction, and deposition of ECM, eventually leading to tissue fibrosis.

Specifications

Assay Points
500
Assay Target Type
Kit
Assay Technology
HTRF
Brand
HTRF
Quantity
1
Therapeutic Area
Cardiovascular
NASH/Fibrosis
Unit Size
500 Assay Points

Video gallery

How it works

Assay principle

The alpha-SMA assay is based on a TR-FRET sandwich immunoassay format comprising two antibodies, one labelled with Eu3+-Cryptate (donor) and the other with d2 (acceptor). The antibodies specifically bind to Alpha-SMA, and the proximity of donor and acceptor leads to a fluorescent TR-FRET signal.

Biomarkers how it works assay principle alpha sma 62asmapeg 62asmapeh 62asmapej
Assay protocol

Two-plate assay protocol For added flexibility, the assay can be run under a two-plate assay protocol, where cells are plated, treated, and lysed in a culture plate. For detection, lysates are subsequently transferred into a 96- or 384-well low volume detection microplate, where the HTRF reagents are added. This protocol enables the cells' viability and confluence to be monitored. The detection reagents may be pre-mixed and added in a single dispensing step for direct detection. The assay can be run with frozen cell lysates or fresh cells in culture.

Biomarkers how it works assay protocol alpha sma 62asmapeg

 

Assay validation

Specificity for Alpha-SMA isoform validated by siRNA experiments

The human hepatic stellate cell line LX-2* and the mouse fibroblast cell line NIH/3T3 were plated in culture-treated 96-well plates (10,000 cells/well) and incubated for 24h at 37°C - 5% CO2. The day after, the cells were transfected with an Alpha-SMA siRNA or with a negative control siRNA for 24h, and then treated or not with 2.5 ng/mL of TGF-ß1 for an additional 24 hours. After medium removal, the cells were lysed with supplemented lysis buffer #3 (50 µL for LX-2, or 200 µL for NIH/3T3) for 30 minutes at RT under gentle shaking. 16 µL of lysate were transferred into a low volume white microplate and 4 µL of the HTRF® Alpha-SMA detection antibodies were added. On both cell lines, transfection with the Alpha-SMA siRNA led to a huge decrease of the HTRF specific signal (~ 60 to 70%) compared to the cells transfected with the negative control siRNA, demonstrating that the HTRF® Alpha-SMA assay is specific for a-SMA isoform and does not cross-react with other actin isoforms.

​* LX-2 cell line provided by EMD Millipore (product number #SCC064)

Assay validation alpha sma 1
Assay validation alpha sma 2
Alpha-SMA expression upon differentiation of HSCs into myofibroblasts

​The human hepatic stellate cell line LX-2* was plated in a culture-treated 96-well plate (50,000 cells/well) in complete culture medium, and incubated at 37°C - 5% CO2. The day after, the cells were treated with increasing concentrations of TGF-beta1 for 48 hours. After medium removal, the cells were lysed with 50 µL of supplemented lysis buffer #3, and 16 µL of lysate were transferred into a low volume white microplate before the addition of 4 µL of the HTRF® Alpha-SMA detection antibodies. TGF-beta1 treatment induces a two-fold increase of Alpha-SMA expression level, highlighting the differentiation of HSCs into myofibroblasts.​

​* LX-2 cell line provided by EMD Millipore (product number #SCC064)

 

Assay validation alpha sma 3
Primary HLFs differentiation into myofibroblasts in lung fibrosis

Primary human lung fibroblasts (HLFs) were plated in a culture-treated 96-well plate (20,000 cells/well) in complete culture medium and incubated overnight at 37°C - 5% CO2. Cells were then incubated for an additional 24 hours in serum-free medium before treatment with increasing concentrations of TGF-beta1 for 48 hours. After medium removal, cells were lysed with 50 µL of supplemented lysis buffer #3 for 30 minutes at RT under gentle shaking, and 16 µL of lysate were transferred into a low volume white plate before adding 4 µL of the HTRF® Alpha-SMA detection antibodies. The long-term treatment of cells with TGF-beta1 results in a four-fold increase in Alpha-SMA expression level, highlighting the differentiation of HLFs into myofibroblasts.

 

Assay validation alpha sma 4
Alpha-SMA expression upon differentiation of fibroblasts into myofibroblasts

The mouse fibroblast cell line NIH/3T3 was plated in a culture-treated 96-well plate (6,250 and 12,500 cells/well) in complete culture medium, and incubated at 37°C - 5% CO2. The day after, the cells were treated with increasing concentrations of TGF-ß1 for 48 hours in serum-free and antibiotic-free culture medium supplemented with 0.2% BSA. After medium removal, the cells were lysed with 200 µL of supplemented lysis buffer #3 for 30 minutes at RT under gentle shaking, and 16 µL of lysate were transferred into a low volume white microplate before the addition of 4 µL of the HTRF® Alpha-SMA detection antibodies. The HTRF signal was recorded after an overnight incubation. TGF-beta1 long-term treatment results in a three-fold increase of Alpha-SMA expression level, which demonstrates the differentiation of fibroblasts into myofibroblasts.

Assay validation alpha sma 5
HTRF Alpha-SMA assay compared to Western Blot

NIH/3T3 cells were seeded in a T175 flask, and incubated for 2 days at 37°C. After medium removal, the cells were lysed for 30 minutes at RT under gentle shaking. Soluble supernatants were collected after a 10-minute centrifugation. Serial dilutions of the cell lysate were performed in the supplemented lysis buffer, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of the HTRF® Alpha-SMA detection reagents. Equal amounts of lysates were used for a side-by-side comparison with Western Blot. Using HTRF® Alpha-SMA detection reagents, just 200 cells were sufficient for minimal signal detection, while 800 cells were needed to detect a significant Western Blot signal. Thus the HTRF® Alpha-SMA assay is 4-fold more sensitive than the Western Blot.

Assay validation alpha sma 6

 

Simplified pathway

TGF-beta signaling pathway

TGF-beta is a profibrotic cytokine that represents the main myofibroblast inducer. The SMAD-dependent TGF-beta signaling pathway involving the activation of the transcription factors SMAD2/3 leads to ACTA2 gene transcription and expression of alpha-SMA (a-Smooth Muscle Actin). This specific actin isoform is incorporated into actin stress fibers and gives the cells a strong contractile activity characteristic of differentiated myofibroblasts. TGF-beta also signals through SMAD-independent pathways by activating the TAK1-dependent kinases p38, JNK and NF-kappaB, as well as AKT and ERK kinases.

Biomarkers tab4 tgf beta signaling pathway 62asmapeg

 

Resources

1-2 of 2 Resources
Guide Icon
Guide
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.

Guide Icon
Guide
Improving immunotherapy by targeting the tumor stroma

Guide to How Cellular Actors of the Tumor Microenvironment Challenge Immunotherapies

Since the early 2000s, significant scientific...

SDS, COAs, Manuals and more Illuminator

SDS, COAs, Manuals and more

Are you looking for technical documents for this product. We have housed them in a dedicated section., click on the links below to explore.

Scroll Icon